Dr. Jacqueline H. Barnea, DBA is NESA’s Strategic Liaison. To this transformational project, she brings her global vision, adaptability, flexibility, and out-of-the box innovative thinking.
Having been awarded her Doctorate in International Business Law / Business Administration (DBA) from the Sorbonne-Pantheon University in Paris, Jacqueline first taught graduate-level students and high-level corporate executive courses in decision-making, comparative management, international negotiations, medical decision and marketing, while initially preparing for a corporate law and academic career, directly operational for NESA.
Dr. Barnea redirected her legal and managerial career towards biotechnology with the mission of PIF-to-Patients. Jacqueline envisioned/is co-founder of BioIncept LLC. and immediate Past President /CEO. A clinical-stage biotechnology, this intellectual property portfolio holding company develops the translation of the PreImplantation Factor (PIF) to clinics. PIF, nature’s evolutionarily conserved immune modulator with applications extending to local and systemic immune homeostasis, transplant acceptance and neurorepair/regeneration. Discovered by Eytan R. Barnea, MD FACOG, under Jacqueline’s leadership and guidance, PIF went from idea to successful completion of Phase I, FAST-TRACK designated FDA-approved clinical trial, obtaining from the FDA 3 Orphan Drug Designations and maintaining ongoing NIH support to address matters of US National Interest: radiation, neurological disease and polytrauma.